Tazarotene Gel Research Articles

Combining Tazarotene Gel and UVB Phototherapy

Combining Tazarotene Gel and UVB Phototherapy

Clinical safety of tazarotene in the treatment of plaque psoriasis

Oral retinoids are effective in the treatment of psoriasis, but their use is limited by concerns for teratogenic potential and systemic side effects. Tazarotene is a novel acetylenic retinoid undergoing clinical trials for the topical treatment of mild-to-moderate plaque psoriasis. The safety and tolerability of tazarotene 0.1% and 0.05% gels were examined in a series of preclinical and clinical trials. In preclinical studies topically applied tazarotene gel was nonmutagenic, noncarcinogenic, and nonteratogenic. Tazarotene gel was not sensitizing, phototoxic, or photosensitizing in a series of studies in human volunteers. Treatment-related systemic adverse effects were not observed in clinical trials involving approximately 2000 patients treated with tazarotene 0.1% or 0.05% gel for periods of up to 1 year. Adverse effects appear limited to manageable, mainly mild-to-moderate local skin irritation. (J Am Acad Dermatol 1997; 37:S25–S32.)

Tazarotene gel: Efficacy and safety in plaque psoriasis

Tazarotene is the first of a new generation of acetylenic retinoids developed for the topical treatment of mild-to-moderate plaque psoriasis. Controlled clinical trials have demonstrated that once-daily tazarotene 0.05% and 0.1% gels are effective in improving and reducing clinical signs and symptoms of psoriasis on trunk and limb lesions and difficult-to-treat elbow and knee plaques. Tazarotene has a rapid onset of action indicated by significant improvements as early as the first week of treatment. Sustained beneficial effects have been observed in some patients for up to 12 weeks after the cessation of therapy. Compared with twice-daily fluocinonide 0.05% cream, once-daily tazarotene 0.05%, and 0.1% gels were similarly effective in reducing plaque elevation. Once-daily tazarotene 0.05% and 0.1% gels demonstrated a more prolonged therapeutic effect after discontinuation than twice-daily fluocinonide cream. Tazarotene is generally well tolerated, with adverse events limited to local irritation. Tazarotene appears to be an effective addition to the currently available treatments for plaque psoriasis. (J Am Acad Dermatol 1997; 37:S33–38.)

Tazarotene gel: Efficacy and safety in plaque psoriasis

<h2>Abstract</h2> Tazarotene is the first of a new generation of acetylenic retinoids developed for the topical treatment of mild-to-moderate plaque psoriasis. Controlled clinical trials have demonstrated that once-daily tazarotene 0.05% and 0.1% gels are effective in improving and reducing clinical signs and symptoms of psoriasis on trunk and limb lesions and difficult-to-treat elbow and knee plaques. Tazarotene has a rapid onset of action indicated by significant improvements as early as the first week of treatment. Sustained beneficial effects have been observed in some patients for up to 12 weeks after the cessation of therapy. Compared with twice-daily fluocinonide 0.05% cream, once-daily tazarotene 0.05%, and 0.1% gels were similarly effective in reducing plaque elevation. Once-daily tazarotene 0.05% and 0.1% gels demonstrated a more prolonged therapeutic effect after discontinuation than twice-daily fluocinonide cream. Tazarotene is generally well tolerated, with adverse events limited to local irritation. Tazarotene appears to be an effective addition to the currently available treatments for plaque psoriasis. (J Am Acad Dermatol 1997; 37:S33–38.)

Tazarotene gel, a new retinoid, for topical therapy of psoriasis: Vehicle-controlled study of safety, efficacy, and duration of therapeutic effect

Background: Topical therapy providing initial improvement and maintenance of effect after treatment of the large majority of patients with limited, mild to moderate psoriasis is not presently available. Previous topical retinoids have generally been either ineffective or too irritating for therapy of psoriasis. Objective: Our purpose was to evaluate a new topical retinoid, tazarotene, in the treatment of stable plaque psoriasis during treatment and posttreatment periods. Methods: In a double-blind manner, 324 patients were randomly selected to receive tazarotene 0.1% or 0.05% gel, or vehicle control, once daily for 12 weeks and were then followed up for 12 weeks after treatment. Results: Of the total, 318 patients could be evaluated. Tazarotene gels were superior ( p < 0.05) to vehicle, often as early as treatment week 1, in all efficacy measures: plaque elevation, scaling, and erythema; treatment response; percentage treatment success (patients with ≥50% improvement); and time to initial success. Efficacy was equivalent on target lesion sites (trunk or limbs and knees or elbows) and overall. A sustained therapeutic effect was observed for 12 weeks after treatment. Tazarotene gel was cosmetically acceptable. There was low systemic absorption, limiting toxicity to local irritation. Conclusion: Once-daily tazarotene was effective and safe as a topical monotherapy for plaque psoriasis, providing rapid reduction of signs and symptoms. (J Am Acad Dermatol 1997;37:85–92.)

Tazarotene gel gains US approval for psoriasis and acne

Tazarotene gel gains US approval for psoriasis and acne

Tazarotene heads for success in psoriasis

The full results of a double-blind, phase III study of tazarotene involving patients with psoriasis were presented at this year’s Dermatology Update [ Montreal, Canada; October 1995 ]. The data showed that tazarotene gel significantly reduced lesion development, compared with placebo, and was well tolerated. These results bode well for the new retinoid, which was submitted to the US FDA in June 1995 for marketing approval as a treatment for acne and psoriasis.